A Glimmer of Hope for Crohn's Patients: Stoked Bio's Latest Leap Forward

A Game-Changer on the Horizon: Disc Medicine's Bitopertin and the FDA's Looming Decision

Viking Therapeutics Rockets Skyward: Is Their Obesity Drug the Next Market Game-Changer?

A Regulatory Stumble: FDA Puts Brakes on Moderna's Flu Vaccine Hopes

A Bumpy Road Ahead? FDA Hits Pause on Moderna's Flu Shot Application

Vertex's Pivotal Moment: Beyond CF, What to Expect from Q4 Earnings

The Market's Two Minds: Lilly's High-Stakes Game Meets Housing's Quiet Comeback

Moderna's Big Turnaround: Why Jim Cramer is Eyeing 2026 for Revenue Growth

AstraZeneca's Bold Bet: Charging Hard into China's Obesity Drug Race and Beyond

The AI Wave: Is it Time for 'Monkey Business' to Evolve in Pharma Research?

The J.P. Morgan Healthcare Conference 2026: Day 2 Unpacked

Alnylam's Ambitious Five-Year Vision: Betting Big on Amvuttra and Beyond

Pune's Biotech Boom: How Startups Are Reshaping Pharma and Life Sciences

Friday's Market Pulse: The Club's Essential Watchlist for the Trading Day

Cathie Wood's Bold Bet on Biotech: A Deep Dive into Gene Editing's Future

Biohaven's Balancing Act: Cash Cushion Grows, But So Does the Dilution Shadow

Unpacking the Ambition: Trump's Most-Favored-Nation Drug Pricing Push

A Game-Changer for Assembly Bio: Gilead's Nod Sends Stock Soaring

Incyte Unveils Game-Changing Myelofibrosis Data at ASH 2025

ASH 2025: Glimmers of Hope and Big Strides in Blood Disorders

A Glimmer of Hope: Syndax's Novel AML Drug Shines Bright at ASH Meeting

A New Dawn in Cancer Detection: Freenome's Bold Move Towards Public Markets

Vinay Prasad Sounds the Alarm: Media Missteps and Harvard’s Choices Are Hurting Biotech

A New Beacon of Hope: Bristol Myers Squibb's Breyanzi Achieves Fifth FDA Approval

Sensei Biotherapeutics Shares Skyrocket: The Science Behind the Stock Surge

The Anticipation Builds: ASH 2025 and the Evolving Landscape of Blood Cancer Therapies

The FDA's Bold New Vision: Could One Clinical Trial Be Enough for Drug Approval?

A Glimmer of Hope for Hair Loss Sufferers: Cosmo Pharma's Breezula Delivers in Landmark Trial

A New Challenger Emerges: Could Viridian's Eye Disease Drug Outshine Amgen's Blockbuster Tepezza?

CVS Health Reaches $37.8 Million Settlement Over Allegations of Faulty Insulin Refills

ADC Therapeutics Shares Face Brutal Sell-Off After Disappointing Clinical Trial Results

A Beacon of Hope: Capricor's Cell Therapy Shows Remarkable Heart Improvements in Duchenne Patients

The Quest for Immortality: Billions Bet on Beating Time Itself

The Next Frontier: Unpacking the Future of Deep Tech

A Lasting Solution: Beating the Weight Regain Cycle Post-GLP-1s

Shattuck Labs Takes Flight: Goldman Sachs' Bold 'Buy' Rating Ignites Biotech Stock

Eli Lilly's Zepbound Gets a Significant Price Drop: What It Means for Patients and the Market

A Bold Bet on the Future: Regeneron's $150M Investment in Gene Writing

A Beacon of Hope: Reviva Pharmaceuticals' Brilaroxazine Achieves Pivotal Milestones in Schizophrenia Treatment